glp 1 going gray GLP-1 Compounding: When Innovation May Mean Liability Stigma and GLP-1s for Weight

This review describes available AD drugs and several novel approaches presently being investigated

GLP-1s have become impossible to ignore

This is anecdotal and not universally experienced, but if you notice increased redness and itching at the injection site , the levocarnitine may be contributing

Key questions that remain unanswered for danuglipron include: Long-term weight maintenance beyond one year Cardiovascular outcomes and mortality benefits Comparative effectiveness against established injectable GLP-1 therapies Real-world adherence rates and tolerability in broader populations Patients and healthcare professionals should await peer-reviewed publication of complete trial data before drawing definitive conclusions about danuglipron's clinical utility

The primary concern relates not to direct drug interactions between most injectable GLP-1 agonists and levothyroxine, but rather to the potential impact on thyroid monitoring and the theoretical risk associated with thyroid C-cell tumours observed in animal studies

10.1182/blood-2005-07-2933 126